CD64-targeted HO-1 RNA interference enhances chemosensitivity in orthotopic model of acute myeloid leukemia and patient-derived bone marrow cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yong, Seok-Beom | - |
dc.contributor.author | Chung, Jee Young | - |
dc.contributor.author | Kim, Seong Su | - |
dc.contributor.author | Choi, Hyung Seok | - |
dc.contributor.author | Kim, Yong-Hee | - |
dc.date.accessioned | 2021-07-30T05:13:47Z | - |
dc.date.available | 2021-07-30T05:13:47Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/3751 | - |
dc.description.abstract | Acute myeloid leukemia is the most frequent and life-threatening blood cancer. The main treatment is chemotherapy, sometimes followed by stem cell transplant. Resistance to chemotherapy and hepatotoxicity of the CD33-targeted therapy require an alternative therapeutic strategy. Here, we report CD64-targeted RNA interference as a novel AML therapy, which was delivered by a recombinant fusion protein of CD64-binding antibody and nona-arginine (sR9). The sR9-mediated heme oxygenase-1 siRNA (siHO-1) delivery efficiently enhanced apoptotic response to daunorubicin of AML cells and AML-targeted HO-1 silencing improved chemotherapy and prolonged survival in orthotopic myeloid leukemia model. CD64 expression was verified and HO-1-silencing-mediated chemo-sensitization was also validated in leukemic blast cells originated from AML M4/M5 patient's bone marrow. Collectively, CD64-targeted RNA interference could be a promising strategy for AML therapy and AML-targeted HO-1 suppression is expected to improve the chemotherapeutic effect in future clinical trials. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | CD64-targeted HO-1 RNA interference enhances chemosensitivity in orthotopic model of acute myeloid leukemia and patient-derived bone marrow cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Hee | - |
dc.identifier.doi | 10.1016/j.biomaterials.2019.119651 | - |
dc.identifier.scopusid | 2-s2.0-85075869364 | - |
dc.identifier.wosid | 000508746600050 | - |
dc.identifier.bibliographicCitation | BIOMATERIALS, v.230, pp.1 - 11 | - |
dc.relation.isPartOf | BIOMATERIALS | - |
dc.citation.title | BIOMATERIALS | - |
dc.citation.volume | 230 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 11 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.subject.keywordPlus | ACUTE MYELOGENOUS LEUKEMIA | - |
dc.subject.keywordPlus | HEME OXYGENASE-1 | - |
dc.subject.keywordPlus | GEMTUZUMAB OZOGAMICIN | - |
dc.subject.keywordPlus | CATHEPSIN-B | - |
dc.subject.keywordPlus | ANTIBODY | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | TRANSPLANTATION | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | RECEPTORS | - |
dc.subject.keywordAuthor | Acute myeloid leukemia | - |
dc.subject.keywordAuthor | Monocytic myeloid leukemia | - |
dc.subject.keywordAuthor | CD64-Targeted fusion protein | - |
dc.subject.keywordAuthor | HO-1 silencing-mediated chemo-sensitization | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0142961219307501?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.